

Compensatory Mechanism for Homeostatic Blood Pressure in Gene-disrupted Mice

Journal of Biological Chemistry

282, 2891-2898

DOI: [10.1074/jbc.m608057200](https://doi.org/10.1074/jbc.m608057200)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The Soluble Epoxide Hydrolase as a Pharmaceutical Target for Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2007, 50, 225-237.	0.8	159
2	Proteinuria increases oxylipid concentrations in VLDL and HDL but not LDL particles in the rat. <i>Journal of Lipid Research</i> , 2007, 48, 1792-1800.	2.0	40
3	DiscrEET regulators of homeostasis: epoxyeicosatrienoic acids, cytochrome P450 epoxygenases and vascular inflammation. <i>Trends in Pharmacological Sciences</i> , 2007, 28, 448-452.	4.0	63
4	Soluble epoxide hydrolase gene deletion reduces survival after cardiac arrest and cardiopulmonary resuscitation. <i>Resuscitation</i> , 2008, 76, 89-94.	1.3	60
5	Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. <i>Nature Genetics</i> , 2008, 40, 529-537.	9.4	163
6	Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. <i>Nature Neuroscience</i> , 2008, 11, 1311-1318.	7.1	314
7	Transcriptomic and Metabonomic Profiling of Obesity-Prone and Obesity-Resistant Rats under High Fat Diet. <i>Journal of Proteome Research</i> , 2008, 7, 4775-4783.	1.8	81
8	Inhibition of Soluble Epoxide Hydrolase Does Not Protect against Endotoxin-Mediated Hepatic Inflammation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 327, 707-715.	1.3	29
9	Salt Loading Increases Urinary Excretion of Linoleic Acid Diols and Triols in Healthy Human Subjects. <i>Hypertension</i> , 2008, 51, 755-761.	1.3	14
10	Soluble Epoxide Hydrolase Gene Deletion Is Protective Against Experimental Cerebral Ischemia. <i>Stroke</i> , 2008, 39, 2073-2078.	1.0	158
11	Epoxyeicosatrienoic acids and the soluble epoxide hydrolase are determinants of pulmonary artery pressure and the acute hypoxic pulmonary vasoconstrictor response. <i>FASEB Journal</i> , 2008, 22, 4306-4315.	0.2	100
12	Opposite Regulation of Cholesterol Levels by the Phosphatase and Hydrolase Domains of Soluble Epoxide Hydrolase. <i>Journal of Biological Chemistry</i> , 2008, 283, 36592-36598.	1.6	51
13	Epoxyeicosatrienoic Acid Agonist Rescues the Metabolic Syndrome Phenotype of HO-2-Null Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 331, 906-916.	1.3	129
14	Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 564-569.	3.3	150
15	Soluble epoxide hydrolase inhibition: targeting multiple mechanisms of ischemic brain injury with a single agent. <i>Future Neurology</i> , 2009, 4, 179-199.	0.9	53
16	Alteration in plasma testosterone levels in male mice lacking soluble epoxide hydrolase. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2009, 297, E375-E383.	1.8	43
17	Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 297, F740-F748.	1.3	121
18	Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation. <i>Journal of Lipid Research</i> , 2009, 50, 204-213.	2.0	225

#	ARTICLE	IF	CITATIONS
19	Variation in the human soluble epoxide hydrolase gene and risk of restenosis after percutaneous coronary intervention. <i>BMC Cardiovascular Disorders</i> , 2009, 9, 48.	0.7	11
20	Mammalian epoxide hydrolases in xenobiotic metabolism and signalling. <i>Archives of Toxicology</i> , 2009, 83, 297-318.	1.9	189
21	Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 794-805.	21.5	527
22	Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation. <i>British Journal of Pharmacology</i> , 2009, 156, 284-296.	2.7	87
23	Protective actions of epoxyeicosatrienoic acid: Dual targeting of cardiovascular PI3K and KATP channels. <i>Journal of Molecular and Cellular Cardiology</i> , 2009, 46, 978-988.	0.9	39
24	Quantitative Profiling Method for Oxylipin Metabolome by Liquid Chromatography Electrospray Ionization Tandem Mass Spectrometry. <i>Analytical Chemistry</i> , 2009, 81, 8085-8093.	3.2	292
25	HPLC/MS/MS-Based Approaches for Detection and Quantification of Eicosanoids. <i>Methods in Molecular Biology</i> , 2009, 579, 161-187.	0.4	8
26	EDHF: an update. <i>Clinical Science</i> , 2009, 117, 139-155.	1.8	289
27	Homozygosity for the EPHX2 K55R polymorphism increases the long-term risk of ischemic stroke in men: a study in Swedes. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 94-103.	0.7	46
28	Targeting Epoxides for Organ Damage in Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2010, 56, 329-335.	0.8	53
29	Cytochrome P450 Pathway Contributes to Methanandamide-induced Vasorelaxation in Rat Aorta. <i>Cardiovascular Drugs and Therapy</i> , 2010, 24, 379-389.	1.3	6
30	Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs. <i>European Journal of Pharmaceutical Sciences</i> , 2010, 40, 222-238.	1.9	76
31	Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model. <i>Biochemical Pharmacology</i> , 2010, 79, 880-887.	2.0	115
32	Insight in modulation of inflammation in response to diclofenac intervention: a human intervention study. <i>BMC Medical Genomics</i> , 2010, 3, 5.	0.7	34
33	Expression and Regulation of Soluble Epoxide Hydrolase in Adipose Tissue. <i>Obesity</i> , 2010, 18, 489-498.	1.5	80
34	Kynurenine is an endothelium-derived relaxing factor produced during inflammation. <i>Nature Medicine</i> , 2010, 16, 279-285.	15.2	418
35	Detection of omega-3 oxylipins in human plasma and response to treatment with omega-3 acid ethyl esters. <i>Journal of Lipid Research</i> , 2010, 51, 2074-2081.	2.0	118
36	Detection of omega-3 oxylipins in human plasma and response to treatment with omega-3 acid ethyl esters. <i>Journal of Lipid Research</i> , 2010, 51, 2074-2081.	2.0	97

#	ARTICLE	IF	CITATIONS
37	Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation. <i>Journal of Molecular and Cellular Cardiology</i> , 2010, 48, 331-341.	0.9	152
38	Epoxyeicosatrienoic acids " Novel mechanism and pharmacological therapy of chronic renocardiac syndrome. <i>Medical Hypotheses</i> , 2011, 76, 550-552.	0.8	4
39	Soluble Epoxide Hydrolase Inhibitors and Heart Failure. <i>Cardiovascular Therapeutics</i> , 2011, 29, 99-111.	1.1	63
40	12- and 15-lipoxygenases in human carotid atherosclerotic lesions: Associations with cerebrovascular symptoms. <i>Atherosclerosis</i> , 2011, 215, 411-416.	0.4	68
41	Effects of Dynamic Exercise on Plasma Arachidonic Acid Epoxides and Diols in Human Volunteers. <i>International Journal of Sport Nutrition and Exercise Metabolism</i> , 2011, 21, 471-479.	1.0	20
42	Modulation of cytochrome-derived epoxyeicosatrienoic acids pathway: A promising pharmacological approach to prevent endothelial dysfunction in cardiovascular diseases?. , 2011, 131, 1-17.		50
43	Soluble epoxide hydrolase inhibition, epoxygenated fatty acids and nociception. <i>Prostaglandins and Other Lipid Mediators</i> , 2011, 96, 76-83.	1.0	58
44	Role of cytochrome P450 enzymes in the bioactivation of polyunsaturated fatty acids. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2011, 1814, 210-222.	1.1	177
45	Activation of the Acute Inflammatory Response Alters Cytochrome P450 Expression and Eicosanoid Metabolism. <i>Drug Metabolism and Disposition</i> , 2011, 39, 22-29.	1.7	107
46	Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 9038-9043.	3.3	130
47	Redox Regulation of Soluble Epoxide Hydrolase by 15-Deoxy- Δ^2 -Prostaglandin J ₂ Controls Coronary Hypoxic Vasodilation. <i>Circulation Research</i> , 2011, 108, 324-334.	2.0	50
48	Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice. <i>FASEB Journal</i> , 2011, 25, 703-713.	0.2	113
49	Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2012, 302, R321-R330.	0.9	38
50	Novel soluble epoxide hydrolase inhibitor protects mitochondrial function following stress. <i>Canadian Journal of Physiology and Pharmacology</i> , 2012, 90, 811-823.	0.7	37
51	Soluble epoxide hydrolase expression in a porcine model of arteriovenous graft stenosis and anti-inflammatory effects of a soluble epoxide hydrolase inhibitor. <i>American Journal of Physiology - Cell Physiology</i> , 2012, 303, C278-C290.	2.1	27
52	Inhibition of Soluble Epoxide Hydrolase Limits Niacin-induced Vasodilation in Mice. <i>Journal of Cardiovascular Pharmacology</i> , 2012, 60, 70-75.	0.8	9
53	Allergic Asthmatics Show Divergent Lipid Mediator Profiles from Healthy Controls Both at Baseline and following Birch Pollen Provocation. <i>PLoS ONE</i> , 2012, 7, e33780.	1.1	54
54	Epoxides and Soluble Epoxide Hydrolase in Cardiovascular Physiology. <i>Physiological Reviews</i> , 2012, 92, 101-130.	13.1	302

#	ARTICLE	IF	CITATIONS
55	Attenuation of Cisplatin-Induced Renal Injury by Inhibition of Soluble Epoxide Hydrolase Involves Nuclear Factor κ B Signaling. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 341, 725-734.	1.3	52
57	Inhibition of Soluble Epoxide Hydrolase Attenuates High-Fat-Diet-Induced Hepatic Steatosis by Reduced Systemic Inflammatory Status in Mice. <i>PLoS ONE</i> , 2012, 7, e39165.	1.1	95
58	Mechanism of the Sex Difference in Endothelial Dysfunction after Stroke. <i>Translational Stroke Research</i> , 2013, 4, 381-389.	2.3	38
59	Altered behavioral phenotypes in soluble epoxide hydrolase knockout mice: Effects of traumatic brain injury. <i>Prostaglandins and Other Lipid Mediators</i> , 2013, 104-105, 18-24.	1.0	22
60	Soluble epoxide hydrolase: Gene structure, expression and deletion. <i>Gene</i> , 2013, 526, 61-74.	1.0	174
61	Differential cardiotoxicity in response to chronic doxorubicin treatment in male spontaneous hypertension-heart failure (SHHF), spontaneously hypertensive (SHR), and Wistar Kyoto (WKY) rats. <i>Toxicology and Applied Pharmacology</i> , 2013, 273, 47-57.	1.3	22
62	Impact of Soluble Epoxide Hydrolase and Epoxyeicosanoids on Human Health. <i>Annual Review of Pharmacology and Toxicology</i> , 2013, 53, 37-58.	4.2	438
63	Adenosine A _{2A} receptor modulates vascular response in soluble epoxide hydrolase-null mice through CYP-epoxygenases and PPAR γ . <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2013, 304, R23-R32.	0.9	20
64	Soluble Epoxide Hydrolase Inhibition Does Not Prevent Cardiac Remodeling and Dysfunction After Aortic Constriction in Rats and Mice. <i>Journal of Cardiovascular Pharmacology</i> , 2013, 61, 291-301.	0.8	26
65	Arg287Gln variant of EPHX2 and epoxyeicosatrienoic acids are associated with insulin sensitivity in humans. <i>Prostaglandins and Other Lipid Mediators</i> , 2014, 113-115, 38-44.	1.0	36
66	Aberrant Soluble Epoxide Hydrolase and Oxylipin Levels in a Porcine Arteriovenous Graft Stenosis Model. <i>Journal of Vascular Research</i> , 2014, 51, 269-282.	0.6	1
67	Protection from hypertension in mice by the Mediterranean diet is mediated by nitro fatty acid inhibition of soluble epoxide hydrolase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 8167-8172.	3.3	79
68	Soluble epoxide hydrolase-dependent regulation of myogenic response and blood pressure. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2014, 306, H1146-H1153.	1.5	33
69	The Pharmacology of the Cytochrome P450 Epoxygenase/Soluble Epoxide Hydrolase Axis in the Vasculature and Cardiovascular Disease. <i>Pharmacological Reviews</i> , 2014, 66, 1106-1140.	7.1	122
70	Design and discovery of soluble epoxide hydrolase inhibitors for the treatment of cardiovascular diseases. <i>Expert Opinion on Drug Discovery</i> , 2014, 9, 229-243.	2.5	28
71	Cytochrome P450 and Lipoxygenase Metabolites on Renal Function. , 2015, 6, 423-441.		21
72	Sexually dimorphic phenotype of arteriolar responsiveness to shear stress in soluble epoxide hydrolase-knockout mice. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2015, 309, H1860-H1866.	1.5	16
73	Whatever Happened to the Epoxyeicosatrienoic Acid-Like Endothelium-Derived Hyperpolarizing Factor? The Identification of Novel Classes of Lipid Mediators and Their Role in Vascular Homeostasis. <i>Antioxidants and Redox Signaling</i> , 2015, 22, 1273-1292.	2.5	20

#	ARTICLE	IF	CITATIONS
74	Epoxyeicosatrienoic Acids, Hypertension, and Kidney Injury. <i>Hypertension</i> , 2015, 65, 476-482.	1.3	71
75	Inhibition of soluble epoxide hydrolase attenuates hepatic fibrosis and endoplasmic reticulum stress induced by carbon tetrachloride in mice. <i>Toxicology and Applied Pharmacology</i> , 2015, 286, 102-111.	1.3	70
76	Cytochrome P450-Derived Lipid Mediators and Vascular Responses. , 2015, , 209-231.		0
77	Soluble epoxide hydrolase activity regulates inflammatory responses and seizure generation in two mouse models of temporal lobe epilepsy. <i>Brain, Behavior, and Immunity</i> , 2015, 43, 118-129.	2.0	42
78	Effect of Soluble Epoxide Hydrolase on the Modulation of Coronary Reactive Hyperemia: Role of Oxylipins and PPAR γ . <i>PLoS ONE</i> , 2016, 11, e0162147.	1.1	22
79	Vasopressin lowers renal epoxyeicosatrienoic acid levels by activating soluble epoxide hydrolase. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 311, F1198-F1210.	1.3	2
80	Deletion of soluble epoxide hydrolase enhances coronary reactive hyperemia in isolated mouse heart: role of oxylipins and PPAR γ . <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2016, 311, R676-R688.	0.9	17
81	Salt Sensitivity of Blood Pressure. <i>Hypertension</i> , 2016, 68, e7-e46.	1.3	347
82	Sexually dimorphic adaptation of cardiac function: roles of epoxyeicosatrienoic acid and peroxisome proliferator-activated receptors. <i>Physiological Reports</i> , 2016, 4, e12838.	0.7	14
83	Metabolic perturbations of postnatal growth restriction and hyperoxia-induced pulmonary hypertension in a bronchopulmonary dysplasia model. <i>Metabolomics</i> , 2017, 13, 1.	1.4	23
84	Nanobody Based Immunoassay for Human Soluble Epoxide Hydrolase Detection Using Polymeric Horseradish Peroxidase (PolyHRP) for Signal Enhancement: The Rediscovery of PolyHRP?. <i>Analytical Chemistry</i> , 2017, 89, 6248-6256.	3.2	55
85	Dietary Docosahexaenoic Acid and <i>trans</i> -10, <i>cis</i> -12- Δ C Conjugated Linoleic Acid Differentially Alter Oxylipin Profiles in Mouse Periuterine Adipose Tissue. <i>Lipids</i> , 2017, 52, 399-413.	0.7	9
86	Cytochrome P450 eicosanoids in cerebrovascular function and disease. , 2017, 179, 31-46.		40
87	Cytochrome P450-derived eicosanoids and heart function. , 2017, 179, 47-83.		97
88	Insulin induces a shift in lipid and primary carbon metabolites in a model of fasting-induced insulin resistance. <i>Metabolomics</i> , 2017, 13, 1.	1.4	9
89	Beyond detoxification: a role for mouse mEH in the hepatic metabolism of endogenous lipids. <i>Archives of Toxicology</i> , 2017, 91, 3571-3585.	1.9	14
90	Soluble epoxide hydrolase activation by S-nitrosation contributes to cardiac ischemia-reperfusion injury. <i>Journal of Molecular and Cellular Cardiology</i> , 2017, 110, 70-79.	0.9	12
91	Soluble Epoxide Hydrolase Inhibitor and 14,15-Epoxyeicosatrienoic Acid-Facilitated Long-Term Potentiation through cAMP and CaMKII in the Hippocampus. <i>Neural Plasticity</i> , 2017, 2017, 1-14.	1.0	12

#	ARTICLE	IF	CITATIONS
92	Vascular Endothelial Over-Expression of Human Soluble Epoxide Hydrolase (Tie2-sEH Tr) Attenuates Coronary Reactive Hyperemia in Mice: Role of Oxylipins and ω -Hydroxylases. PLoS ONE, 2017, 12, e0169584.	1.1	10
93	Generation and characterization of epoxide hydrolase 3 (EPHX3)-deficient mice. PLoS ONE, 2017, 12, e0175348.	1.1	13
94	Abnormal lipoprotein oxylipins in metabolic syndrome and partial correction by omega-3 fatty acids. Prostaglandins Leukotrienes and Essential Fatty Acids, 2018, 128, 1-10.	1.0	34
95	Deletion of soluble epoxide hydrolase attenuates mice Hyperoxic acute lung injury. BMC Anesthesiology, 2018, 18, 48.	0.7	17
96	Soluble Epoxide Hydrolase Plays a Vital Role in Angiotensin II-Induced Lung Injury in Mice. Shock, 2018, 50, 589-594.	1.0	19
97	Lipid profiling in serum from apolipoprotein E-knock out mice fed with different diets and its application to the study of the regulatory effect on lipid metabolism. Food and Function, 2018, 9, 5103-5114.	2.1	12
98	Mammalian Epoxide Hydrolases. , 2018, , 308-325.		1
99	An improved Ultra-High Performance Liquid chromatography-tandem mass spectrometry method for simultaneous quantitation of cytochrome P450 metabolites of arachidonic acid in human plasma. Journal of Chromatography A, 2018, 1563, 144-153.	1.8	7
100	Role of oxylipins in cardiovascular diseases. Acta Pharmacologica Sinica, 2018, 39, 1142-1154.	2.8	90
101	Genetic Deletion or Pharmacological Inhibition of Soluble Epoxide Hydrolase Ameliorates Cardiac Ischemia/Reperfusion Injury by Attenuating NLRP3 Inflammasome Activation. International Journal of Molecular Sciences, 2019, 20, 3502.	1.8	21
102	Epoxyeicosatrienoic acids alleviate methionineâ€cholineâ€deficient dietâ€induced nonâ€alcoholic steatohepatitis in mice. Scandinavian Journal of Immunology, 2019, 90, e12791.	1.3	15
103	Serum and Fecal Oxylipins in Patients with Alcohol-Related Liver Disease. Digestive Diseases and Sciences, 2019, 64, 1878-1892.	1.1	35
104	Vitamin D supplementation alters the expression of genes associated with hypertension and did not induce DNA damage in rats. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2019, 82, 299-313.	1.1	10
105	Liver Soluble Epoxide Hydrolase Regulates Behavioral and Cellular Effects of Chronic Stress. Cell Reports, 2019, 29, 3223-3234.e6.	2.9	35
106	CYP-derived eicosanoids: Implications for rheumatoid arthritis. Prostaglandins and Other Lipid Mediators, 2020, 146, 106405.	1.0	20
107	Investigating global gene expression changes in a murine model of cherubism. Bone, 2020, 135, 115315.	1.4	0
108	Pathogenic mechanisms of lipid mediator lysophosphatidic acid in chronic pain. Progress in Lipid Research, 2021, 81, 101079.	5.3	21
109	A thiol redox sensor in soluble epoxide hydrolase enables oxidative activation by intra-protein disulfide bond formation. Redox Biology, 2021, 46, 102107.	3.9	3

#	ARTICLE	IF	CITATIONS
110	Soluble Epoxide Hydrolase as a Stroke Target. , 2012, , 277-294.		1
111	Mammalian Epoxide Hydrolases*. , 2010, , 275-294.		2
112	Opposite Effects of Gene Deficiency and Pharmacological Inhibition of Soluble Epoxide Hydrolase on Cardiac Fibrosis. PLoS ONE, 2014, 9, e94092.	1.1	49
113	Renal Ischemia/Reperfusion Injury in Soluble Epoxide Hydrolase-Deficient Mice. PLoS ONE, 2016, 11, e0145645.	1.1	22
114	Association of gain-of-function EPHX2 polymorphism Lys55Arg with acute kidney injury following cardiac surgery. PLoS ONE, 2017, 12, e0175292.	1.1	19
115	Soluble Epoxide Hydrolase: Potential Target for Inflammation and Inflammation-Driven Cancer. Journal of Carcinogenesis & Mutagenesis, 2017, 08, .	0.3	1
116	Bioactive lipid profiling reveals drug target engagement of a soluble epoxide hydrolase inhibitor in a murine model of tobacco smoke exposure. Journal of Metabolomics, 2015, 1, 1.	0.7	3
117	Insulin resistance and endothelial dysfunction: Are epoxyeicosatrienoic acids the link?. Experimental and Clinical Cardiology, 2009, 14, e41-50.	1.3	13
119	Soluble epoxide hydrolase deficiency inhibits dextran sulfate sodium-induced colitis and carcinogenesis in mice. Anticancer Research, 2013, 33, 5261-5271.	0.5	27
120	Orally active epoxyeicosatrienoic acid analogs in hypertension and renal injury. Advances in Pharmacology, 2022, , .	1.2	0
121	CRISPR/Cas9-mediated inactivation of the phosphatase activity of soluble epoxide hydrolase prevents obesity and cardiac ischemic injury. Journal of Advanced Research, 2023, 43, 163-174.	4.4	7
122	Redox Regulation of Soluble Epoxide Hydrolase—Implications for Cardiovascular Health and Disease. Cells, 2022, 11, 1932.	1.8	4
123	Cardiomyocyte-specific disruption of soluble epoxide hydrolase limits inflammation to preserve cardiac function. American Journal of Physiology - Heart and Circulatory Physiology, 2022, 323, H670-H687.	1.5	6
124	Blood Levels of Endocannabinoids, Oxylipins, and Metabolites Are Altered in Hemodialysis Patients. International Journal of Molecular Sciences, 2022, 23, 9781.	1.8	3
125	Role of epoxyeicosatrienoic acids in cardiovascular diseases and cardiotoxicity of drugs. Life Sciences, 2022, 310, 121122.	2.0	2
126	Lipid mediators generated by the cytochrome P450—Epoxide hydrolase pathway. Advances in Pharmacology, 2023, , 327-373.	1.2	2